Bone and soft tissue sarcomas, tumors of the skin

Саркомы костей, мягких тканей и опухоли кожи

2219-46142782-3687

Publishing House ABV Press

393

EDITORIAL

ОТ РЕДАКЦИИ

Modifying soft tissue sarcoma chemotherapy regimens. Old drugs and new horizons

Модификация режимов химиотерапии сарком мягких тканей. Старые препараты и новые возможности

Fedenko

A. A.

Феденко

А. А.

Russian Federation

Moscow

г. Москва

fedenko@eesg.ru

FGBU N.N. Blokhin Russian Cancer Research CenterФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» МЗ РФ

22112015

3192201202222012022

2015

Fedenko A.A.

Феденко А.А.

https://creativecommons.org/licenses/by/4.0

https://sarbon.abvpress.ru/jour/article/view/393

We report results of single institution trial of 78 STS pts treated with front line high dose doxorubicin with ifosfamide in comparison with 50 pts treated retrospectively with standard MAID regimen. We achieved 44% increase in PFS (from 5 to 7.2 month) and OS (from 10 to 19.2 month) in high dose subgroup (p=0.00001). New regimen showed high activity and durable toxicity profile and can be used routinely only in specialized sarcoma centers across the country.

Проведен сравнительный анализ эффективности лечения 78 больных СМТ, получавших высокодозную химиотерапию режимом HD AI и 50 больных ретроспективно проходивших терапию режимом MAID. Отмечено увеличение ВБП на 44% в высокодозной группе с 5 до 7,2 месяцев и увеличение общей выживаемости с 10 до 19,2 месяцев соответственно (р=0,00001). Новый режим показал высокую эффективность и удовлетворительную переносимость и может быть рекомендован для использования в первую линию лечения на базе специализированных центров по лечению сарком на территории РФ.

soft tissue sarcoma (STS)high dose chemotherapyfront line

саркомы мягких тканей (СМТ)высокодозная химиотерапияпервая линия лечения

1. Patel S.R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R.S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378.

Patel S.R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R.S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378.

2. Billingsley K.G., Burt M.E., Jara E., Ginsberg R.J., Woodruff J.M., Leung D.H., Brennan M.F. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann. Surg. 1999, v. 229 (5), p. 602.

Billingsley K.G., Burt M.E., Jara E., Ginsberg R.J., Woodruff J.M., Leung D.H., Brennan M.F. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann. Surg. 1999, v. 229 (5), p. 602.

3. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing firstline regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 1999, v. 17 (1), p. 150.

Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing firstline regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 1999, v. 17 (1), p. 150.

4. Benjamin R.S., WiernikP.H., Bachur N.R. Adriamycin: a new effective agent in the therapy of disseminated sarcomas Med. Pediatr. Oncol. 1975, v. 1 (1), p. 63.

Benjamin R.S., WiernikP.H., Bachur N.R. Adriamycin: a new effective agent in the therapy of disseminated sarcomas Med. Pediatr. Oncol. 1975, v. 1 (1), p. 63.

5. Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., Lerner H.J., Carbone P.P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 1987, v. 5 (6), p. 840.

Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., Lerner H.J., Carbone P.P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 1987, v. 5 (6), p. 840.

6. Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., Lerner H.J., Carbone P.P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. Clin. Oncol. 1987, v. 5 (6), p. 840.

7. Judson I., Radford J.A., Harris M., Blay J.Y., van Hoesel Q., le Cesne A., van Oosterom A.T., Clemons M.J., Kamby C., Hermans C., Whittaker J., Donato di Paola E., Verweij J., Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2001, v. 37 (7), p. 870.

Judson I., Radford J.A., Harris M., Blay J.Y., van Hoesel Q., le Cesne A., van Oosterom A.T., Clemons M.J., Kamby C., Hermans C., Whittaker J., Donato di Paola E., Verweij J., Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2001, v. 37 (7), p. 870.

8. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 1995, v. 13 (7), p. 1537.

Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 1995, v. 13 (7), p. 1537.

9. Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S., Shiraki M., Frytak S., Parkinson D.R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 1993, v. 11 (7), p. 1269.

Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S., Shiraki M., Frytak S., Parkinson D.R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 1993, v. 11 (7), p. 1269.

10.

10. Borden E.C., Amato D.A., Edmonson J.H., Ritch P.S., Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 1990, v. 66 (5), p. 862.

Borden E.C., Amato D.A., Edmonson J.H., Ritch P.S., Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 1990, v. 66 (5), p. 862.

11.

11. Houridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, v. 23 (10), p. 1477.

Houridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, v. 23 (10), p. 1477.

12.

12. Schoenfeld D.A., Rosenbaum C., Horton J., Wolter J.M., Falkson G., De Conti R.C. Acomparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982, v. 50 (12), p. 2757.

Schoenfeld D.A., Rosenbaum C., Horton J., Wolter J.M., Falkson G., De Conti R.C. Acomparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982, v. 50 (12), p. 2757.

13.

13. Demetri G.D., Elias A.D. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol. Oncol. Clin. North Am. 1995, v. 9 (4), p. 765.

Demetri G.D., Elias A.D. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol. Oncol. Clin. North Am. 1995, v. 9 (4), p. 765.

14.

14. Nielsen O.S., Dombernowsky P., Mouridsen H., Crowther D., Verweij J., Buesa J., StewardW., Daugaard S., van GlabbekeM., KirkpatrickA., TurszT. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer. 1998, v. 78 (12), p. 1634.

Nielsen O.S., Dombernowsky P., Mouridsen H., Crowther D., Verweij J., Buesa J., StewardW., Daugaard S., van GlabbekeM., KirkpatrickA., TurszT. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer. 1998, v. 78 (12), p. 1634.

15.

15. Mouridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, v. 23 (10), p. 1477.

Mouridsen H.T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J.H., van Oosterom A.T., Buesa J., Pinedo H.M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 1987, v. 23 (10), p. 1477.

16.

16. Patel S.R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R.S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378.

Patel S.R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M.A., Hays C., Benjamin R.S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378.

17.

17. Van Oosterom A.T., Mouridsen H.T., Nielsen O.S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., van GlabbekeM., Verweij J. EORTC Soft Tissue and Bone Sarcoma Group Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer. 2002, v. 38 (18), p. 2397.

Van Oosterom A.T., Mouridsen H.T., Nielsen O.S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., van GlabbekeM., Verweij J. EORTC Soft Tissue and Bone Sarcoma Group Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer. 2002, v. 38 (18), p. 2397.

18.

18. Antman K.H., Ryan L., Elias A., Sherman D., Grier H.E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J. Clin. Oncol. 1989, v. 7 (1), p. 126.

Antman K.H., Ryan L., Elias A., Sherman D., Grier H.E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J. Clin. Oncol. 1989, v. 7 (1), p. 126.

19.

19. Nielsen O.S., Judson I., van Hoesel Q., le Cesne A., Keizer H.J., Blay J.Y., van Oosterom A., Radford J.A., Svancárová L., Krzemienlecki K., Hermans C., van Glabbeke M., Oosterhuis J.W., Verweij J. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2000, v. 36 (1), p. 61.

Nielsen O.S., Judson I., van Hoesel Q., le Cesne A., Keizer H.J., Blay J.Y., van Oosterom A., Radford J.A., Svancárová L., Krzemienlecki K., Hermans C., van Glabbeke M., Oosterhuis J.W., Verweij J. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2000, v. 36 (1), p. 61.

20.

20. Cerny T., Leyvraz S., von Briel T., Küpfer A., Schaad R., Schmitz S.F., Honegger P., Sessa C., Brunner J., Boddy A.V. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 1999, v. 10 (9), p. 1087.

Cerny T., Leyvraz S., von Briel T., Küpfer A., Schaad R., Schmitz S.F., Honegger P., Sessa C., Brunner J., Boddy A.V. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 1999, v. 10 (9), p. 1087.

21.

21. Buesa J.M., López-Pousa A., Martín J., Antón A., García del Muro J., Bellmunt J., Arranz F., Valentí V., Escudero P., Menéndez D., Casado A., Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann. Oncol. 1998, v. 9 (8), p. 871.

Buesa J.M., López-Pousa A., Martín J., Antón A., García del Muro J., Bellmunt J., Arranz F., Valentí V., Escudero P., Menéndez D., Casado A., Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann. Oncol. 1998, v. 9 (8), p. 871.

22.

22. Van Oosterom A.T., Mouridsen H.T., Nielsen O.S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., van GlabbekeM., Verweij J. EORTC Soft Tissue and Bone Sarcoma Group Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer. 2002, v. 38 (18), p. 2397.

23.

23. Palumbo R., Palmeri S., Antimi M., Gatti C., Raffo P., Villani G., Toma S. Phase II study of continuous-infusion highdose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann. Oncol. 1997, v. 8 (11), p. 1159.

Palumbo R., Palmeri S., Antimi M., Gatti C., Raffo P., Villani G., Toma S. Phase II study of continuous-infusion highdose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann. Oncol. 1997, v. 8 (11), p. 1159.

24.

24. Le Cesne A., Antoine E., Spielmann M., Le Chevalier T., Brain E., Toussaint C., Janin N., Kayitalire L., Fontaine F., Genin J. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 1995, v. 13 (7), p. 1600.

Le Cesne A., Antoine E., Spielmann M., Le Chevalier T., Brain E., Toussaint C., Janin N., Kayitalire L., Fontaine F., Genin J. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 1995, v. 13 (7), p. 1600.

25.

25. Rahal A.S. et al. High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. J. Clin. Oncol. 30, 2012 (suppl; abstr. 10044).

Rahal A.S. et al. High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. J. Clin. Oncol. 30, 2012 (suppl; abstr. 10044).

26.

26. Lorigan P., Verweij J., Papai Z., Rodenhuis S., Le Cesne A., Leahy M.G., Radford J.A., van Glabbeke M.M., Kirkpatrick A., Hogendoorn P.C., Blay J.Y. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 2007, v. 25 (21), p. 3144.

Lorigan P., Verweij J., Papai Z., Rodenhuis S., Le Cesne A., Leahy M.G., Radford J.A., van Glabbeke M.M., Kirkpatrick A., Hogendoorn P.C., Blay J.Y. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 2007, v. 25 (21), p. 3144.

27.

27. Bramwell V.H., Mouridsen H.T., Santoro A., Blackledge G., Somers R., Verweij J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 1993, v. 31, Suppl. 2, p. 180.

Bramwell V.H., Mouridsen H.T., Santoro A., Blackledge G., Somers R., Verweij J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 1993, v. 31, Suppl. 2, p. 180.

28.

28. Judson I., Verweij J., Gelderblom H., Hartmann J.T., Schöffski P., Blay J.Y., Kerst J.M., Sufliarsky J., Whelan J., Hohenberger P., Krarup-Hansen A., Alcindor T., Marreaud S., Litière S., Hermans C., Fisher C., Hogendoorn P.C., Dei Tos A.P., van der Graaf W.T. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014, v. 15 (4), p. 415.

Judson I., Verweij J., Gelderblom H., Hartmann J.T., Schöffski P., Blay J.Y., Kerst J.M., Sufliarsky J., Whelan J., Hohenberger P., Krarup-Hansen A., Alcindor T., Marreaud S., Litière S., Hermans C., Fisher C., Hogendoorn P.C., Dei Tos A.P., van der Graaf W.T. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft tissue sarcoma: a randomized controlled phase 3 trial. Lancet Oncol. 2014, v. 15 (4), p. 415.

29.

29. Bramwell V.H., Anderson D., CharetteM.L. Sarcoma Disease Site Group Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst. Rev. 2003.

Bramwell V.H., Anderson D., CharetteM.L. Sarcoma Disease Site Group Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst. Rev. 2003.

30.

30. Blay J.Y., van Glabbeke M., Verweij J., van Oosterom A.T., Le Cesne A., Oosterhuis J.W., Judson I., Nielsen O.S. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. ur J. Cancer. 2003, v. 39 (1), p. 64.

Blay J.Y., van Glabbeke M., Verweij J., van Oosterom A.T., Le Cesne A., Oosterhuis J.W., Judson I., Nielsen O.S. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. ur J. Cancer. 2003, v. 39 (1), p. 64.